Anti-PD-1/PD-L1 therapy augments lenvatinib’s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Viswanath Gunda*, Benjamin Gigliotti*, Tameem Ashry, Dorothy Ndishabandi, Michael McCarthy, Zhiheng Zhou, Salma Amin, Kyu Eun Lee, Tabea Stork, Lori Wirth, Gordon J Freeman, Alessandro Alessandrini, Sareh Parangi * Authors contributed equally to this work Short Title: Combining Lenvatinib and anti-PD-1/PD-L1 therapy in orthotopic murine anaplastic thyroid cancer Corresponding Author: Sareh Parangi, MD Harvard Medical School Massachusetts General Hospital Department of Surgery Division of General and Gastrointestinal Surgery Wang Ambulatory Care Center 460 15 Parkman Street Boston, MA 02115 Email: sparangi@partners.org Phone: 617-643-4806 Fax: 617- 643-4802 Accepted Article This article is protected by copyright. All rights reserved. Thi   s article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.32041